Ethical, legal and social issues in maintence of Biobanks
Ethical issues are commonly present in many aspects of Biobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to a biobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research using human tissue material and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.
American Society for Bioethics and Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxford shire, UK, CFP: Global Forum on Bioethics in Research Foundation Merieux, France, Hands On Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida – USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.
According to estimates from the World Bank, global healthcare spending increased at a CAGR of 6.97% from 2003 to 2013, from USD 3,786 Billion in 2003 to USD 7,427 Billion in 2013. In this period, public healthcare spending increased at a CAGR of 7.28%, from USD 2,198 Billion in 2003 to USD 4,440 Billion in 2013. This high growth rate, along with the substantial size of healthcare spending, will act as an important driver for biobanks, hospitals and gene banks, which are the major end-user segments of the biopreservation media & equipment market.
- Ownership, Property Rights and Commercialization in Relation to Biobanking
- Ethical considerations surrounding biobanking and biorepository operation.
- Legal and Ethical Framework For Collaborative Biobanking Across Europe
- Factors Influencing Biobanks Prices
- Ethical issues & future use of samples
Related Conference of Ethical, legal and social issues in maintence of Biobanks
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
22nd World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
17th International Conference on Human Genetics and Genetic Diseases
Ethical, legal and social issues in maintence of Biobanks Conference Speakers
Recommended Sessions
- Biobanking Informatics
- Biorepository & Biospecimen
- Cryopreservation Methods
- Data Enrichment in Biobanks
- Ethical, legal and social issues in maintence of Biobanks
- Fertility biobanks
- Frontiers in Bioengineering and Biomaterials
- Germplasm Bank
- Next Generation Biobanking
- Quality Management Systems for Biobanking
- Stemcell Banking
- Tissue engineering
- Vitrification
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)

